Misplaced Pages

Revision as of 23:08, 2 June 2008

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) No issues specified. Please specify issues, or remove this template. (Learn how and when to remove this message)

Template:Biologically based therapy Orthomolecular medicine is a form of complementary and alternative medicine with the goal to preventing and treating disease with vitamins and nutrient suppliments. The term "orthomolecular" was first coined in 1967 by Nobel Prize winner Linus Pauling in a paper on micronutrients and psychiatry to express the idea of the right molecules in the right amounts (ortho is Greek for right). In this paper he indicated that the right molecules are "substances that are normally present in the human body". Orthomolecular medicine began with a particular focus upon mental illness, and orthomolecular psychiatry remains a major subdiscipline. Proponents state that orthomolecular treatments are based on patients' personal biochemistries and employ naturally-occurring or bioequivalent (bio)molecules, particularly nutrients such as vitamins, dietary minerals, proteins, antioxidants, amino acids, lipotropes, prohormones, dietary fiber, fatty acids and other similar substances.

Some megavitamin therapies can be classified as components of orthomolecular medicine. Orthomolecular practitioners often recommend levels beyond the Recommended Daily Allowance, especially for vitamin C, and prescribe the removal of unhealthy foods from the diet. Megavitamin therapies have become relatively popular, with a survey in 2002 finding that approximately one in twenty-five US adults use high doses of vitamins as a form of therapy, with this being particularly common in people diagnosed with cancer.

Nutrients are useful in preventing and treating some illnesses, but the mainstream medical consensus is that the broad claims of disease treatment by advocates of orthomolecular medicine are unsubstantiated by the available evidence. The American Medical Association stated in 1997 that "much of the dietary intervention stressed by alternative healers is prudent and reasonable", but described as a "myth" the idea that "most diseases are caused by faulty diets and can be prevented by nutritional interventions". Critics have described some aspects of orthomolecular medicine as food faddism or quackery. Research on nutrient supplementation in general suggests that some nutritional supplements might be beneficial, and that others might be harmful.

History and development

Orthomolecular medicine has counted Antoine Laurent Lavoisier, James Lind and Christiaan Eijkman, among others, as early researchers in the field. Although these figures preceded later controversies and labels, they have been identified as orthomolecular by their emphasis on the role of nutrition in treating disease. In the 1920s Dr. Max Gerson developed Gerson therapy, a strict diet which he claimed could treat many diseases. In 1933 Drs. Wilfred and Evan Shute began to use vitamin E to treat heart disease. Some of the concepts frequently utilized in orthomolecular medicine, such as individual biochemical variation, inborn error of metabolism, and exogeneous supply of essential substances in therapy debuted in scientific and medical papers early in the 20 th century. Orthomolecular megavitamin therapies, such as with tocopherols and ascorbates, date back to the 1930s.

In 1948 Dr. William McCormick theorized that vitamin C deficiency played an important role in many diseases, and began to use large doses in patients. In the 1950s American doctor Frederick Klenner also experimented with the use of vitamin C megadosage as a therapy for a wide range of illnesses, most notably polio, and authored 28 research papers during his career. McCormick and Klenner influenced biochemist Dr. Irwin Stone, who extensively researched vitamin C and received the first patent for its commerical use. Irwin Stone found that all living beings have vitamin C. Further, nearly all vertebrates produce vitamin C, and produce much more when stressed. Some primates, including humans, do not produce vitamin C, and Stone claimed that this was due to a genetic defect which he called hypoascorbemia. Based on a rat's production of vitamin C, a 70 kg human would produce between 1.8 and 4 grams of vitamin C, and a stressed human up to 15.2 grams. This contrasts with the current Dietary Reference Intake, which maintains that 90 mg is adequate, and increases that to 120 mg if pregnant. Based on the levels of vitamin C in other vertebrates, Stone believed that ascorbate was not a trace vitamin but was required in humans in large daily amounts. He produced four papers between 1965 and 1967 to back up this assertion. In 1966 Stone met Linus Pauling and sparked Pauling's interest in vitamin C.

Concurrent to the developments with vitamin C, orthomolecular psychiatry began to be developed in the early 1950s by a group of biochemists and psychiatrists who believed that certain vitamin deficiencies were associated with mental illness. In particular, psychiatrists Drs. Humphry Osmond and Abram Hoffer began to treat schizophrenia with high doses of niacin, continuing work done by Dr. William Kaufman, who used niacinamide. Incidental to this effort, Hoffer contributed to the discovery that niacin could treat dyslipidemia in 1954-5.

In 1967, Linus Pauling introduced the expression orthomolecular medicine to describe one aspect of medicine, and the term "orthomolecular therapy", as published in Science in 1968, to express the idea of the right molecules in the right amounts. Pauling subsequently defined "orthomolecular medicine" as "the treatment of disease by the provision of the optimum molecular environment, especially the optimum concentrations of substances normally present in the human body" or as "the preservation of good health and the treatment of disease by varying the concentrations in the human body of substances that are normally present in the body and are required for health."

Since 1968 the field has diversified, but the term orthomolecular is still associated with Pauling's advocacy of multi-gram doses of vitamin C for optimal health. Partly for this reason, detractors of orthomolecular medicine have described the practice entirely in terms of megadose nutrient therapy. Cassileth, a widely quoted critic of Pauling's ideas, asserts: "In 1968, the Nobel-prize-winning scientist Linus Pauling coined the term "orthomolecular" to describe the treatment of disease with large quantities of nutrients." In this way, criticism of orthomolecular medicine has, to a large extent, been confused with much older medical traditions of high-dose vitamin therapies, such as earlier "megadose" usages of retinol and ergocalciferol or synthetic pharmaceutical analogues, such as menadione. However, such definitions of orthomolecular therapy are not synonymous with Pauling's definition. Interest in vitamin C has been renewed, beginning with the discovery that intravenous vitamin C can achieve plasma concentrations up to 70-fold higher than oral vitamin C. A 2005 paper in the Proceedings for the National Academy of Sciences noted that vitamin C selectively killed cancer cells in vitro. This paper noted that, although the original observational studies of vitamin C were based on intravenous administration, the subsequent double-blind placebo-controlled studies used oral ascorbate. In 2007, the researchers demonstrated how vitamin C in vivo could possibly kill cancer cells. A recent historical study of the past ten years has found three patients whose tumors shrank after receiving intravenous vitamin C along with other alternative and conventional treatments. The authors of the study claimed that the case studies "only signficant treatment" for these patients was vitamin C. However, this is far from conclusive, and studies are currently planned at the McGill University.

Research since the 1960s has branched out further into nutrients besides niacin and vitamin C. Dr. David Horrobin did important work with essential fatty acids, which have played an increasingly important part in orthomolecular medicine.

Scope

Although orthomolecular medicine is based on the idea that nutrititional imbalances should be corrected before illness occurs, and consequently is not easily integrated into any single branch of medicine, its claims are particularly associated with psychiatry, in the field of orthomolecular psychiatry, and oncology, where Linus Pauling reported that Vitamin C could slow the progression of, and even reverse, cancer. As time went on Pauling came to believe that there was a deliberte and concerted effort to denigrate, distort and dissemble about his efforts, Ewan Cameron the Scottish oncologist, who collaborated with Pauling, very reluctantly came to agree as he believed to perceive mounting evidence to support the Pauling's allegations of bad fath.

Proponents of orthomolecular medicine claim that scientists associated with orthomolecular medicine had identified specific biochemical anomalies that account for many cases of bipolar disorder, schizophrenia, and some similar manifestations, such as, in one case, an previously undescribed copper toxicity disorder.

Based on investigational scientific studies, single-blind and double-blind randomized controlled trials, clinical experience, and case histories, claims have been made that therapeutic nutrition can prevent treat, and sometimes cure acne, bee stings, burns, cancer, the common cold, drug addiction, drug overdose, heart diseases, acute hepatitis, herpes, influenza, mononucleosis, mushroom poisoning, neuropathy & polyneuritis (including multiple sclerosis), osteoporosis, polio, alcoholism, allergies, arthritis, autism, epilepsy, hypertension, hypoglycemia, migraine, clinical depression, learning disabilities, retardation, mental and metabolic disorders, skin problems, and hyperactivity," Raynaud's disease, heavy metal toxicity, radiation sickness, * Pyroluria, schizophrenia, shock, snakebite, spider bite, tetanus toxin and viral pneumonia.

However, most orthomolecular practitioners do not claim to be able to treat all diseases. As Abram Hoffer wrote in 1989: "Nor is orthomolecular treatment a replacement for standard treatment. A proportion of patients will require orthodox treatment, a proportion will do much better on orthomolecular treatment, and the rest will need a skillful blend of both." For example, Hoffer admits that in his experience, acute and not chronic schizophrenia responds to niacin.

Principles

Orthomolecular medicine claims that it is preferable to recognize and correct any possible anomalies in metabolism at an early stage, before they cause disease. Orthomolecular medicine posits that many typical diets are insufficient for long term health; thus, orthomolecular medical diagnoses and treatment often focus on the use of nutrients such as vitamins, dietary minerals, proteins, antioxidants, amino acids, ω-3 fatty acids, ω-6 fatty acids, dietary fiber, and short and long chain fatty acids, although a wide range of other substances are used, such as lipotropes and prohormones. Abram Hoffer wrote a foreword to one edition of Weston Price's 1930 description of his travels and observations of the health and diet among "primitive" peoples who did not consume processed foods, and were spared the ravages of "degenerative" diseases.

Orthomolecular nutriton and therapy attempts to provide optimal amounts of micronutrients. Most often, "optimal" has been a matter of the clinical judgment of the orthomolecular practitioner, who gives these compounds in accord with the clinical symptoms of the patient and the practioner's judgment of what is appropriate, rather than the published dietary reference intakes of these nutrients. Modern orthomolecular practitioners also use a wide range of laboratory analyses, including those for amino acids, organic acids, vitamins and minerals, functional vitamin status, hormones, immunology, microbiology, and gastrointestinal function. However, many of these tests are not employed by mainstream medicine for common diagnostic use.

In the early years of orthomolecular medicine, supplementation usually meant high-dose, single-agent nutrient therapy. Today, orthomolecular practitioners use many substances: amino acids, enzymes, hormones, vitamins, minerals, or derivate substances in an effort to supply what they see as optimum dosages of these substances.

Frequently supplementation with relatively large doses of vitamins is given, and the name megavitamin therapy is popularly associated with the area. Megavitamin therapy is the administration of large amounts of vitamins, often many times greater than the recommended dietary allowance (RDA). The nominal ratio of dose to RDA to qualify for the term "megavitamin therapy" has been a matter of minor semantic debate.

Administration of short-chain fatty acids in orthomolecular practice is usually done by increasing the level of dietary fiber. The fatty acids are produced by fermentation of the fiber in the colon, then absorbed into the body. Attempts are also made to aid this process by a combination of prebiotics and mucopolysaccharides. Long chain fatty acids, such as the omega-3 fatty acids alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), may also be given directly, in food or in capsules.

Prevalence

Orthomolecular medicine is practiced by few conventional medical practitioners. Orthomolecular treatments are instead more common in complementary and alternative medicine fields, increasingly being integrated into over the counter retail products, naturopathic medical textbooks and mainstream pharmaceuticals.

A survey released in May 2004 by the National Center for Complementary and Alternative Medicine focused on who used complementary and alternative medicine (CAM), what was used, and why it was used in the United States by adults age 18 years and over during 2002. The survey reported uses in the previous 12 months that include orthomolecular related uses: Nonvitamin, nonmineral, natural products 18.9%, Diet-based therapies 3.5%, Megavitamin therapy 2.8%. The survey did not include other popular related categories such as juicing, supplemental antioxidants, essential fatty acids, amino acids, enzymes and others.

Another recent CAM survey reported that 12% of liver disease patients used the antioxidant silymarin, more than 6% used megavitamins among others, and that "in all, 74% of patients reported using CAM in addition to the medications prescribed by their physician, but 26% did not inform their physician of their CAM use." The use of high doses of vitamins is also common in people who have been diagnosed with cancer, although usage depends of the type of cancer and ranges from 26% to 35% among prostate cancer survivors up to 75% to 87% in breast cancer survivors.

Criticism

Methodology

Orthomolecular medicine advocates claim that the methods of orthomolecular medicine overlap with those of both natural medicine and mainstream medicine. The International Society for Orthomolecular Medicine has conventionally-trained doctors among its members and authors, and the notable founders of orthomolecular medicine have all had professional degrees. The leading orthomolecular medicine website, Orthomolecular Medicine Online, run by the Journal of Orthomolecular Medicine, discusses differences between orthomolecular medicine and mainstream medicine,

Amongst the differences, mainstream medicine attaches great importance to evidence-based medicine, particularly to rigorous double-blind randomized controlled trials that test if a treatment is genuinely effective and exclude the placebo effect. Orthomolecular medicine proponents, on the other hand, believe that such studies overemphasize uniformity, under-emphasize variability between patients, and reduce choice and health freedom.

Mainstream medicine also avoids the use of new treatments whose effects are unknown, instead favoring extensively tested, clinically proven drugs. Even with this level of caution, up to 20% of drugs may subsequently have unrecognized, serious adverse reactions, requiring the later addition of the "black box warning", or withdrawal from market.

The skepticism about orthomolecular medicine comes in part because some of its proponents make claims more broad than those supported by scientific research, particularly claims that may contradict the results of clinical trials, and rely instead on less reliable observational studies, clinical and anecdotal experience, single blinded controlled tests, and case histories. Proponents of orthomolecular medicine argue that, despite the extensive testing of pharmaceuticals, some medications are withdrawn after approval, due to serious adverse events, and the FDA regulatory methodology and relationship with the pharmaceutical industry has been criticized.

Views on safety and efficacy

The conventional view amongst mainstream medical physicians is that most orthomolecular therapies are insufficiently proven for clinical use, that the scientific foundations are weak, and that the studies that have been performed are too few and too open to disputed interpretation. This form of alternative medicine has therefore been described as "food faddism" and even "quackery", with critics arguing that it is based upon an "exaggerated belief in the effects of nutrition upon health and disease".

Many mainstream medical institutions dismiss orthomolecular medicine entirely. The American Medical Association describes as "myths" the ideas that vitamin and mineral deficiencies are widespread, that the causes of most diseases are poor diets, or that most diseases can be prevented by nutritional supplements. Similarly, the American Cancer Society comments that the current scientific evidence does not "support use of orthomolecular therapy for most of the conditions for which it is promoted". They stated some supplements have exhibited benefits for certain conditions, while a few have been confirmed to be harmful, and that the consumption of nutritious foods is the best recognized method to obtain vitamins, minerals, and nutrients crucial for good health. In another example, an adviser on alternative medicine to the National Institutes of Health, stated that "Scientific research has found no benefit from orthomolecular therapy for any disease" and a recent medical textbook also states that there is "no evidence that megavitamin or orthomolecular therapy is effective in treating any disease." Proponents of orthomolecular medicine counter that vitamins and nutrients are now used in conventional medicine as treatments for disease, such as megadose niacin and fish oil for dyslipidemias, 6000-25,000 iu vitamin E per day for the lipid disorder, abetalipoproteinemia, and megavitamin therapies for over a dozen amino acid metabolism disorders.

Dietary supplements, such as those used in orthomolecular medicine, are less regulated than pharmaceuticals in the United States. Furthermore, a recent meta-analysis in JAMA has suggested that supplementation with combinations of beta carotene, vitamin A, and vitamin E may increase mortality, and this risk may be particularly high in smokers. An essential regulatory difference is that pharmaceuticals must be proven safe and effective to the satisfaction of the FDA before they can be marketed, whereas supplements must be proven unsafe before regulatory action can be taken. A number of orthomolecular US supplements are available in pharmaceutical versions that are sometimes quite similar in strength and general content, or in other countries are pharmaceuticals. The US regulations also have provisions to recognize a general level of safety for established nutrients that can forgo new drug safety tests. Proponents of nutritional supplement use have argued that the lower level of regulation results in cost savings for American consumers, pointing to higher supplement prices in Europe, where some supplements are more tightly regulated or even unavailable.

Relation to mainstream medicine

Aspects of orthomolecular therapy remain controversial among mainstream medical organizations and physicians, who consider many aspects to be lacking sufficient RCT-based evidence. In contrast, orthomolecular proponents argue that many mainstream nutritional studies, both recent and historical, provide investigational and clinical support for their treatments and recommendations. They also argue that orthomolecular therapies are intrinsically less likely to cause dangerous side-effects or harm, since they utilize only chemicals that are normally present in the body. Supporters claim that some aspects of orthomolecular medicine, and in particular the optimal nutrition subset, have support in mainstream scientific research in a variety of areas:

• In 2002, a study of 231 young adult prisoners concluded that antisocial behavior and violence was reduced by supplementation with vitamins, minerals, and essential fatty acids. A replicating is study is planned.

• Greater than the RDA of selenium may reduce the overall incidence of cancers; this effect is strongest in people who had low selenium levels before treatment.

• Greater than the RDA of vitamin D may reduce the risk of cancer in post-menopausal women. It may also increase the immune response to a wide range of viruses, fungi and bacteria.

• Greater than the RDA of "A, B₆, C and E plus zinc", folic acid and selenium reduce the incidence of specific cancers

• Studies finding that supplementation of long-chain omega-3 essential fatty acids reduced the incidence of cardiac mortality in secondary prevention trials

• Early studies finding that vitamin E alone and vitamin C & E together reduce coronary disease mortality

• Studies finding that niacin, selenium, zinc vitamin C alone and vitamin E alone and vitamin C & E together reduce overall mortality rates

• Bruce Ames's studies on the effects of vitamins on genetic diseases and biochemical aging processes

• The advocacy of daily multivitamins in cancer prevention by Ames, by a JAMA review article for "chronic disease prevention in adults" and by an NEJM Editorial.

Some of these findings have been reported as not consistent with other studies. For example, a subsequent meta-analysis failed to find benefit to single isomeric alpha tocopheryl ester forms of vitamin E supplementation and alpha tocopheryl ester supplementation might increase the risk for congestive heart failure. The Shutes decades earlier did specifically caution about tocopherol dosage and slow buildup rates for CHF patients and those with pre-existing rheumatic heart problems; modern orthomolecular medicine has different specific nutrient recommendations for CHF patients. Reconciling and confirming the conclusions of individual nutritional studies is a subject of ongoing research.

These studies all come from mainstream medical sources that do not claim to support orthomolecular doctrine, and in at least some cases, explicitly reject claims of orthomolecular proponents that nutritional supplements are desirable. Ames supports daily Dietary Reference Intake multivitamin supplements as a public-policy solution to the lack of vegetables in United States diets, but has not endorsed global use of megavitamin therapy propounded by orthomolecular medicine.

Orthomolecular proponents, such as Robert Cathcart, who predicts that 120+ grams per day intravenous vitamin C should cure severe acute respiratory syndrome and has used up to 250 grams IV vitamin C per day, have been criticised for not having any conventional medical trials of such intravenous vitamin C treatments.

The orthomolecular field remains controversial among mainstream medical organizations, including the American Cancer Society, the American Psychiatric Association, the National Institute of Mental Health, the American Academy of Pediatrics, CHAMPUS, and the Canadian Paediatric Society. A number of individuals and organizations contest the claims, benefits, degree of evidence and toxicity. Based on testing with dosages well below orthomolecular recommendations, Linus Pauling has been criticized for making overbroad claims for the efficacy of vitamin C but Paulings' claims have received some support from tests closer to the orthomolecular recommendations during the last few years.

The relationship of mainstream medicine to orthomolecular proponents has often been adversarial; orthomolecular proponents argue that mainstream medical claimants confuse orthomolecular medicine with other, less science based modalities. The American Academy of Pediatrics labelled orthomolecular medicine a "cult" in 1976, in response to claims that orthomolecular medicine could cure childhood psychoses and learning disorders.

Conventional health professionals see orthomolecular medicine as encouraging individuals to dose themselves with large amounts of vitamins and other nutrients without conventional supervision, which they worry might be damaging to health. Rare risks of non-orthomolecular "mega" dosages of vitamin relatives, which frequently involved pharmaceutical analogues such as synthetic menadione, unsupervised misuse, deliberate abuse and earlier medical treatments, may include increased risk of coronary heart disease, hypertension, thrombophlebitis, peripheral neuropathy, ataxia, neurological effects, liver toxicity, congenital abnormalities, spontaneous abortion, gouty arthritis, jaundice, kidney stones, and diarrhea. Megavitamin proponents point to an almost zero level of deaths caused by vitamins, even with large overdoses, compared to the significant numbers from pharmaceuticals, including a number of over-the-counter items.

Vitamin E controversy

Vitamin E contains eight related chemicals, which are classed as either tocopherols or tocotrienols. These chemicals also exist as several stereoisomers. In supplements these are usually present in stabilized ester forms, which are converted into the active form in the intestines. Research has focussed on alpha-tocopherol, since this is the form preferentially taken up by the body and the most abundant form in tissues. Alpha-tocopherol is also regarded in orthomolecular medicine as the form with greatest nutritional significance. In supplements this is either a mixture of stereoisomers (all-rac-alpha-tocopherol), or the biological stereoisomer RRR-alpha-tocopherol.

Initial hopes for vitamin E were based on epidemiological studies. These suggested that people who consumed more vitamin E had lower risks of chronic disease, such as coronary heart disease, and led to the idea that vitamin E supplementation could be beneficial. However, these observational studies could not distinguish between if the higher levels of vitamin E improved heath themselves, or if confounding variables were responsible - such as if these people eat a more healthy diet or took more exercise. To distinguish between these possibilities, many randomized controlled trials were performed. Meta-analysis of these controlled clinical trials have not shown any clear benefit from any form of alpha-tocopherol supplementation for preventing chronic disease.

A meta-analysis published in 2005 found that more than 400 units alpha tocopherol per day was associated with an increase in all-cause mortality. Furthermore, a significant relationship was seen between dose and all-cause mortality, with the risk of death increasing in line with the dose. This meta-analysis was criticized on a number of grounds, including that this increase in mortality could have been caused by alpha-tocopherol and beta carotene increasing the risk of lung cancer in heavy smokers. A similar increase in mortality was seen in a 2007 meta-analysis Here, no health risk was seen when all the randomized controlled studies were examined together, but an increase in mortality was detected when the high-quality and low-bias risk trials were examined separately. However, as the majority of these low-bias trials dealt with either elderly people, or people already suffering disease, so these results may not apply to the general population. This meta-analysis was later repeated and extended by the same authors, with the new analysis published by the Cochrane Collaboration; this also concluded that some vitamin E supplements could be harmful.

Orthomolecular recommendations for vitamin E supplementation typically are based on a mixture of tocopheols and tocotrienols. Forms of "vitamin E", which contain mixed R,R,R tocopherols and are also recommended by some orthomolecular practitioners. These other forms of vitamin E have not been examined in as much detail as alpha-tocopherol and may have effects on health that are not produced by the alpha-tocopherol form.

Time and therapeutic priority

Conventional physicians express concern that megavitamin and orthomolecular therapies used solely as alternative treatments by other practitioners, if not successful, may create dangerous delays in obtaining conventional treatments, such as radiation and chemotherapy for cancer. For example, in a highly publicized Canadian controversy, the chemotherapy of a 13-year-old cancer patient, Tyrell Dueck, encountered a delay from legal actions, due to his parents' religious beliefs and interest in alternative treatments such as diet, herbs and vitamins. Orthomolecular medical practitioners and orthomolecular oriented naturopaths have long expressed similar concerns about conventional medicine, particularly with gut related and chronic diseases as well as viral diseases. It is usually possible, however, to combine orthomolecular and conventional treatments.

Use in AIDS

Several orthomolecular related AIDS approaches such as multivitamins, selenium and amino acids are used with reported improvements in patients. High dose vitamin C treatments have long been used clinically by some orthomolecular practitioners to treat AIDS patients. However, a meta-analysis of fifteen clinical trials of vitamin therapy by the Cochrane Collaboration in 2005 found no conclusive evidence that such approaches either reduce symptoms or mortality in HIV-infected adults who are not malnourished, but found some evidence that giving vitamin A to infants with HIV is beneficial. In these situations, mainstream medical criticism arises when orthomolecular approaches are advocated as substitutes for, rather than complements to, current medical treatments such as antiretroviral drugs.

Economic interests and politics

Some orthomolecular proponents claim partisan politics, pharmaceutical industry influence, and competitive considerations to be significant factors. The Linus Pauling Institute's funding comes mostly from National Institutes of Health. Several orthomolecular therapies have been officially sanctioned within Europe and Japan.

Notable supporters of orthomolecular medicine

Journal of Orthomolecular Medicine

The Journal of Orthomolecular Medicine, founded in 1967 as the Journal of Schizophrenia, is the main publication of those involved in Orthomolecular Medicine. Abram Hoffer has written that "We had to create our own journals because it was impossible to obtain entry into the official journals of psychiatry and medicine. Before 1967 I had not found it difficult to publish reports in these journals, and by then I had about 150 articles and several books in the establishment press."

See also

• Alternative medicine
• Health freedom movement
• Life extension
• List of life extension related topics
• Metabolomics
• Megavitamin therapy
• Multivitamin
• Nutritional genomics
• Orthomolecular psychiatry

Citations

1. Orthomolecular medicine Encyclopedia of Alternative Medicine by Patricia Skinner
2. ^ Definition of Orthomolecular medicine at www.orthomed.org Accessed June 2006
3. ^ Pauling L. Orthomolecular Somatic and Psychiatric Medicine “, Communication: Luxembourg and Trier on 18-24 September 1967; Pauling L. 1968b: Orthomolecular Somatic and Psychiatric Medicine J Vital Substances and Diseases of Civilization’’, 14; 1-3.
4. ISOM. About OM
5. Syd Baumel (Aug 2000) "Chapter 5, The Orthomolecular Medical Approach to Depression", "Chapter 6, Vitamin Power", Dealing with Depression Naturally: Complementary and Alternative Therapies, 2nd ed, McGraw-Hill; ISBN 0658002910
6. Roger J. Williams (1998) Biochemical Individuality: The Basis for the Genetotrophic Concept. 2nd ed. Keats Publishing. ISBN 0-87983-893-0
7. Alpha-Lipoic Acid (Thioctic Acid): My Experience
8. Reduction of Cholesterol and Lp(A) in Regression of Coronary Artery Disease: A Case Study
9. Coenzyme Q10: A Novel Cardiac Antioxidant (1997)
10. ^ NCCAM.NIH table 1 on page 8
11. ^ Velicer CM, Ulrich CM (2008). "Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review". J. Clin. Oncol. 26 (4): 665–73. doi:10.1200/JCO.2007.13.5905. PMID 18235127.
12. ^ "ACS : Orthomolecular Medicine". American Cancer Society. 2007-06-19. Retrieved 2008-04-04.
13. Lakhan SE, Vieira KF (2008) Nutritional therapies for mental disorders. Nutr J 7: 2. doi:10.1186/1475-2891-7-2 PMID 18208598
14. Stuart Aaronson et. al. "Cancer Medicine", 2003, BC Decker Inc ISBN 1–55009–213–8, Section 20, p76
15. Nutrition Committee, Canadian Paediatric Society (1990). "Megavitamin and megamineral therapy in childhood". CMAJ. 143 (10): 1009–1013. Retrieved 2008-04-04.
16. ^ Report 12 of the Council on Scientific Affairs: Alternative medicine American Medical Association June 1997, Accessed 21 March 2008
17. ^ Jarvis WT (1983). "Food faddism, cultism, and quackery". Annu. Rev. Nutr. 3: 35–52. doi:10.1146/annurev.nu.03.070183.000343. PMID 6315036.
18. ^ Jukes, T.H. (1990). "Nutrition Science from Vitamins to Molecular Biology". Annual Review of Nutrition. 10 (1): 1–20. doi:10.1146/annurev.nu.10.070190.000245. A short summary is in the journal's preface. Cite error: The named reference "Jukes1990" was defined multiple times with different content (see the help page).
19. ^ Braganza, S.F. (2005). "Fad Therapies". Pediatrics in Review. 26 (10): 371–376. doi:10.1542/pir.26-10-371. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
20. "NIH State-of-the-Science Conference Statement on Multivitamin/Mineral Supplements and Chronic Disease Prevention". NIH Consens State Sci Statements. 23 (2): 1–30. 2006. PMID 17332802.
21. Huang HY, Caballero B, Chang S; et al. (2006). "The efficacy and safety of multivitamin and mineral supplement use to prevent cancer and chronic disease in adults: a systematic review for a National Institutes of Health state-of-the-science conference". Ann. Intern. Med. 145 (5): 372–85. PMID 16880453. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
22. Cite error: The named reference OMHistory was invoked but never defined (see the help page).
23. Wilfred and Evan Shute
24. Roger J. Williams (1998) Biochemical Individuality: The Basis for the Genetotrophic Concept. 2nd ed. Keats Publishing. ISBN 0-87983-893-0
25. Stephen F. Mason. THE SCIENCE AND HUMANISM OF LINUS PAULING (1901-1994). Chemical Society Reviews, 26, no. 1 (February 1997). Section 5, Molecular Medicine: “...Garrod in his book, Inborn Error of Metabolism (1909, 1923)”
26. ^ Menolascino FJ, et al. "Orthomolecular Therapy: Its History and Applicability to Psychiatric Disorders", Child Psychiatry and Human Development, Vol.18(3), Spring 1988, pp 140-1
27. Lois N. Magner A History of Medicine, Informa Healthcare; 2nd edition (June 23, 2005) ISBN 0824740742
28. Beard J. The action of 'trypsin' upon living cells of the Jensen sarcoma. Brit Med J 1906;1:140-141 (Jan. 20, 1906).
29. AscorbateWeb: Timeline from 1935 to 1939
30. MEGADOSES OF VITAMIN C AND DR. WILLIAM J. McCORMICK, McCormick HoF
31. Hidden in Plain Sight: The Pioneering Work of Frederick Robert Klenner, M.D. Andrew W. Saul, online reprint from J Orthomolecular Med, 2007. Vol 22, No 1, p 31-38, Accessed October 2007
32. A posthumous summary of Frederick Klenner's 28 papers. Lendon H. Smith, M.D., Clinical Guide to the Use of Vitamin C - The Clinical Experiences of Frederick R. Klenner, M.D. . Accessed October 2007.
33. The Natural History of Ascorbic Acid in the Evolution of Mammals and Primates, Irwin Stone, 1972
34. Observations On the Dose and Administration of Ascorbic Acid When Employed Beyond the Range of a Vitamin in Human Pathology
35. Council for Responsible Nutrition. Vitamin and Mineral Recommendations
36. STONE. I.: Studies of a Mammalian Enzyme System for Producing Evolutionary Evidence on Man. Amer. J. Phys. Anthrop. 15, 83-85, 1965.
37. STONE. I.: On the Genetic Etiology of Scurvy. Acts Genet. Med. Gemellol. 15, 345-350,1966.
38. STONE, I.: Hypoascorbemia, the Genetic Disease Causing the Human Requirement for Exogenous Ascorbic Acid, Perspectives Bio. Med. 10, 133-134, 1966.
39. STONE, I.: The Genetic Disease, Hyposacorbemia: A Fresh Approach to an Ancient Disease and Some of its Medical Implications, Acta Genet Med. Gemellol. 16, 52-62. 1967.
40. In Memoriam Irwin Stone
41. ISOM. ISOM History of OM
42. Humphry Osmond HoF
43. Walter Kaufman HoF, Kaufman's bibliography
44. Guyton JR (2007). "Niacin in cardiovascular prevention: mechanisms, efficacy, and safety". Curr. Opin. Lipidol. 18 (4): 415–20. doi:10.1097/MOL.0b013e3282364add. PMID 17620858.
45. Orthomolecular psychiatry. Varying the concentrations of substances normally present in the human body may control mental disease,Science 1968 Apr 19;160(825):265-71. (PMID 5641253)
46. Definition of Orthomolecular medicine at www.orthomed.org Accessed June 2006 and What is Orthomolecular Medicine?, Linus Pauling Inst.
47. ^ Cassileth BR. Alternative medicine handbook: the complete reference guide to alternative and complementary therapies. New York: W.W.Norton & Co., 1998:67. Cite error: The named reference "cassileth" was defined multiple times with different content (see the help page).
48. Meyer TC, Angus J. "The effect of large doses of 'Synkavit' in the newborn". Arch Dis Child 1956; vol 31, p. 212-5.
49. Laurance B. "Danger of vitamin K analogues to newborn." Lancet 1955; vol 1, p 819.
50. Sutor AH. New Aspects of Vitamin K Prophylaxis. Semin Thromb Hemost 2003; vol 29, p 373-376 "The problem was solved when synkavit was replaced by low-dose (1 mg) [vitamin K₁ phytomenadion"
51. Annals of Internal Medicine.
52. PNAS. Pharmacologic ascorbic acid concentrations selectively kill cancer cells
53. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo
54. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M (2006). "Intravenously administered vitamin C as cancer therapy: three cases". CMAJ. 174 (7): 937–42. doi:10.1503/cmaj.050346. PMID 16567755. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
55. Assouline S, Miller WH (2006). "High-dose vitamin C therapy: renewed hope or false promise?". CMAJ. 174 (7): 956–7. doi:10.1503/cmaj.060228. PMID 16567756. {{cite journal}}: Unknown parameter |month= ignored (help)
56. Research backs theory that vitamin C shrinks tumours. The Independent, 28 March 2006
57. "Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer" (pdf). Proceeding of the National Academy of Sciences. 73: 3685–3689. 1976. Retrieved 2008-05-31. {{cite journal}}: Unknown parameter |authors= ignored (help)
58. Ewan Cameron, Linus Pauling (1979). Cancer and vitamin C : a discussion of the nature, causes, prevention, and treatment of cancer with special reference to the value of vitamin C. New York: Norton. ISBN 0-393-50000-4.
59. Thomas Hager (1995). Force of Nature: The Life of Linus Pauling. New York: Simon & Schuster. ISBN 0684809095.
60. Clinical Data Shows Vitamin C May Reduce Risks of Cancer, Heart Disease and Variety of Other Health Disorders Genetic Engineering & Biotechnology News , September 24 2007 reporting on Seminars in Preventive and Alternative Medicine (vol. 3, iss. 1, pp. 25-35) Mark A. Moyad, MD, MPH of University of Michigan. accessed October 2007
61. Leung LH, A Stone that Kills two Birds: How Pantothenic Acid Unveils the Mysteries of Acne Vulgaris and Obesity, J. Orthomolecular Med., Vol. 12, 2nd Qtr 1997, Accessed 9 July 2007
62. Plaza SW, Lamson DW. Vitamin K2 in Bone Metabolism and Osteoporosis. Alt Medicine Review, Vol 10, No 1.
63. Hoffer A, et al. Treatment Protocol for Alcoholism. Orthomolecular Medicine News Service, 1 Jul 2005
64. Princeton Brain Bio Center. Brochure, distributed to patients. Skillman, N.J., 1983, The Center.
65. Skinner P, "Orthomolecular Medicine", Gale Encyclopedia of Alternative Medicine: Holistic medicine, Thomson Gale, 2004.
66. Klenner, F.R. (1971). "Observations on the dose and administration of ascorbic acid when employed beyond the range of a vitamin in human pathology" (pdf). J Appl Nutr. 23: 61–88. Retrieved 2008-03-21.
67. ^ Richard P. Huemer MD, Orthomolecular Medicine, Encyclopedia of Complementary Health Practice, Springer Publishing Company, September 18, 1997. available online
68. Hoffer, A. Letter - Megavitamin and megamineral therapy in childhood
69. Huemer RP. A theory of diagnosis for orthomolecular medicine. J Theor Biol 1977 67:625-635. Reprinted in Advances 1984 1(3):53-59.
70. Weston Price (2008) ,Price Pottenger Nutrition; Eight Edition edition . ISBN-10: 0916764206
71. ^ http://orthomed.org/kunin.html Principles That Identify Orthormolecular Medicine: A Unique Medical Specialty by Richard A. Kunin Cite error: The named reference "kunin" was defined multiple times with different content (see the help page).
72. Monica & Gene Spiller (2005) What's with Fiber?, Ch 3, pp 22-29. Basic Health Publications. ISBN 159120111X
73. Gene A. Spiller (2001) CRC Handbook of Dietary Fiber in Human Nutrition, Third Edition. CRC Press. ISBN 0849323878
74. Escudero Alvarez E, González Sánchez P (2006). "Dietary fibre". Nutr Hosp. 21 Suppl 2: 60–71, 61–72. PMID 16771074.
75. Lester M Morrison, OA Schjeide (1974) Coronary heart disease and the mucopolysaccharides (glycosaminoglycans), Charles C Thomas, Springfield, IL,, ISBN 0398029032
76. ^ Orthomolecular Medicine Revisited, Wunderlich RC, Orthomolecular Medicine Online, accessed 6 Nov 2006 Cite error: The named reference "wund" was defined multiple times with different content (see the help page).
77. OMACOR(omega-3-acid ethyl esters), Reliant Pharmaceuticals, Inc.
78. Mason M. "An Old Cholesterol Remedy . NY Times, January 23, 2007
79. Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, Khokar MF, Hoofnagle JH, Seeff LB. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol. 2002 Sep;97(9):2391-7.
80. Orthomolecular Medicine Online
81. Akobeng AK (2005). "Principles of evidence based medicine". Arch. Dis. Child. 90 (8): 837–40. PMID 16040884.
82. Weihrauch TR, Gauler TC (1999). "Placebo--efficacy and adverse effects in controlled clinical trials". Arzneimittelforschung. 49 (5): 385–93. PMID 10367099.
83. DJ Hess, Complementary or Alternative? Stronger vs Weaker Integration Policies Am J Public Health. 2002 October; 92(10): 1579–1581.
84. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of New Black Box Warnings and Withdrawals for Prescription Medications. JAMA. 2002;287:2215-2220.
85. http://www.canstats.org/readdetail.asp?id=542
86. Marcia Angell, (August 24, 2004) The Truth About the Drug Companies: How They Deceive Us and What to Do About It, Random House, 1st ed, ISBN 0-375-50846-5
87. Frei, Emil; Kufe, Donald W.; Holland, James F. (2003). Cancer medicine 6. Hamilton, Ont: BC Decker. p. 76. ISBN 1550092138. Retrieved 2008-04-04.{{cite book}}: CS1 maint: multiple names: authors list (link)
88. Braverman ER, Weissberg E, "Fish Oil As One Therapy in Cardiovascular Risk Factor Reduction," J Orthomolecular Medicine, 3(1), 1987
89. Berra K (2004). "Clinical update on the use of niacin for the treatment of dyslipidemia". J Am Acad Nurse Pract. 16 (12): 526–34. PMID 15645997.
90. "Don't overlook niacin for treating cholesterol problems. If you can conquer or cope with the "niacin flush," this B vitamin can do wonders for cholesterol". Harv Heart Lett. 14 (8): 4–5. 2004. PMID 15100082.
91. M Traber, Linus Pauling Institute, A Kamal-Eldin; "Oxidative stress and vitamin E in anemia", p. 164, Ch 11 in Nutritional Anemia , 2007, SIGHT AND LIFE, Basel, Switzerland " " both hypobetalipoproteinemic or abetalipoproteinemic subjects become vitamin E deficient and develop a characteristic neurologic if they are not given large vitamin E supplements (approximately 10 g per day)"
92. Granot E, Kohen R. Oxidative stress in abetalipoproteinemia patients receiving long-term vitamin E and vitamin A supplementation, AJCN, Vol. 79, No. 2, 226-230, February 2004
93. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C (2007). "Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis". JAMA. 297 (8): 842–57. doi:10.1001/jama.297.8.842. PMID 17327526.{{cite journal}}: CS1 maint: multiple names: authors list (link)
94. "Dietary Supplement Health and Education Act of 1994". Food and Drug Administration. 1994-10-25. Retrieved 2008-04-04.
95. Falloon, W (2005-07-01). "What Do "Regulated" Supplements Cost". Life Extension Magazine. Retrieved 2008-04-04.
96. Orthomolecular Medicine News Service (OMNS) Listing or research and news items favourable to the Orthomolecular point of view
97. What is Orthomolecular Medicine?, Linus Pauling Institute. Accessed online, 1 Nov 2007
98. How safe are vitamins? Orthomolecular Medicine News Service, November 9, 2005 - Accessed August 2006
99. Gesch CB et al, Influence of supplementary vitamins, minerals, and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebo-controlled trial., Br J Psych, 2002, Vol. 181, pp. 22-28 2002
100. Eat it up and be a good boy. The Economist, February 2, 2008
101. ^ Clark LC, Combs GF, Turnbull BW; et al. (1996). "Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group". JAMA. 276 (24): 1957–63. PMID 8971064. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
102. ^ Combs GF, Clark LC, Turnbull BW (1997). "Reduction of cancer mortality and incidence by selenium supplementation". Med. Klin. (Munich). 92 Suppl 3: 42–5. PMID 9342915.{{cite journal}}: CS1 maint: multiple names: authors list (link) Cite error: The named reference "se71a" was defined multiple times with different content (see the help page).
103. ^ Combs GF, Clark LC, Turnbull BW (1997). "Reduction of cancer risk with an oral supplement of selenium". Biomed. Environ. Sci. 10 (2–3): 227–34. PMID 9315315.{{cite journal}}: CS1 maint: multiple names: authors list (link)
104. Combs GF, Clark LC, Turnbull BW (2001). "An analysis of cancer prevention by selenium". Biofactors. 14 (1–4): 153–9. PMID 11568452.{{cite journal}}: CS1 maint: multiple names: authors list (link)
105. Rayman MP (2005). "Selenium in cancer prevention: a review of the evidence and mechanism of action". Proc Nutr Soc. 64 (4): 527–42. PMID 16313696.
106. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007). "Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial". Am. J. Clin. Nutr. 85 (6): 1586–91. PMID 17556697.{{cite journal}}: CS1 maint: multiple names: authors list (link)
107. Cannell JJ, Vieth R, Umhau JC; et al. (2006). "Epidemic influenza and vitamin D". Epidemiol. Infect. 134 (6): 1129–40. doi:10.1017/S0950268806007175. PMID 16959053. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link); lay-summary
108. Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JI (1994). "Megadose vitamins in bladder cancer: a double-blind clinical trial". J. Urol. 151 (1): 21–6. PMID 8254816.{{cite journal}}: CS1 maint: multiple names: authors list (link)
109. Giovannucci E, Stampfer MJ, Colditz GA; et al. (1998). "Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study". Ann. Intern. Med. 129 (7): 517–24. PMID 9758570. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
110. Abe Y, El-Masri B, Kimball KT; et al. (1998). "Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion". Arterioscler. Thromb. Vasc. Biol. 18 (5): 723–31. PMID 9598830. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
111. Harris WS (2003). "n-3 Long-chain polyunsaturated fatty acids reduce risk of coronary heart disease death: extending the evidence to the elderly". Am. J. Clin. Nutr. 77 (2): 279–80. PMID 12540382.
112. "Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico". Lancet. 354 (9177): 447–55. 1999. PMID 10465168.
113. ^ Losonczy KG, Harris TB, Havlik RJ (1996). "Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly". Am. J. Clin. Nutr. 64 (2): 190–6. PMID 8694019.{{cite journal}}: CS1 maint: multiple names: authors list (link)
114. Canner PL, Berge KG, Wenger NK; et al. (1986). "Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin". J. Am. Coll. Cardiol. 8 (6): 1245–55. PMID 3782631. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
115. Clemons TE, Kurinij N, Sperduto RD (2004). "Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13". Arch. Ophthalmol. 122 (5): 716–26. doi:10.1001/archopht.122.5.716. PMID 15136320.{{cite journal}}: CS1 maint: multiple names: authors list (link)
116. Enstrom JE, Kanim LE, Klein MA (1992). "Vitamin C intake and mortality among a sample of the United States population". Epidemiology. 3 (3): 194–202. PMID 1591317.{{cite journal}}: CS1 maint: multiple names: authors list (link)
117. Bruce N Ames, Ilan Elson-Schwab and Eli A Silver (2002). "High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms". American Society for Clinical Nutrition. 75: 616–658. PMID 11916749. Retrieved 2006-08-12.
118. Liu J, Killilea DW, Ames BN (2002). "Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L- carnitine and/or R-alpha -lipoic acid". Proc. Natl. Acad. Sci. U.S.A. 99 (4): 1876–81. doi:10.1073/pnas.261709098. PMID 11854488.{{cite journal}}: CS1 maint: multiple names: authors list (link)
119. Liu J, Head E, Gharib AM; et al. (2002). "Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid". Proc. Natl. Acad. Sci. U.S.A. 99 (4): 2356–61. doi:10.1073/pnas.261709299. PMID 11854529. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
120. Hagen TM, Liu J, Lykkesfeldt J; et al. (2002). "Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress". Proc. Natl. Acad. Sci. U.S.A. 99 (4): 1870–5. doi:10.1073/pnas.261708898. PMID 11854487. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
121. ^ http://www.juvenon.com/pdfs/june05_ames-prescrip.pdf
122. ^ Reason Magazine - Of Mice and Men
123. Fletcher RH, Fairfield KM (2002). "Vitamins for chronic disease prevention in adults: clinical applications". JAMA. 287 (23): 3127–9. PMID 12069676.
124. Fairfield KM, Fletcher RH (2002). "Vitamins for chronic disease prevention in adults: scientific review". JAMA. 287 (23): 3116–26. PMID 12069675.
125. Oakley GP (1998). "Eat right and take a multivitamin". N. Engl. J. Med. 338 (15): 1060–1. PMID 9535672. Retrieved 2008-04-04.
126. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ (2003). "Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials". Lancet. 361 (9374): 2017–23. doi:10.1016/S0140-6736(03)13637-9. PMID 12814711.{{cite journal}}: CS1 maint: multiple names: authors list (link)
127. Lonn E, Bosch J, Yusuf S; et al. (2005). "Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial". JAMA. 293 (11): 1338–47. doi:10.1001/jama.293.11.1338. PMID 15769967. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
128. Saul, AW (2003). "Congestive Heart Failure". DoctorYourself.com. Retrieved 2008-04-04.
129. Jacobs, Joseph; Spencer, John A. D. (2003). Complementary and alternative medicine: an evidence-based approach. St. Louis: Mosby. ISBN 0323020283.{{cite book}}: CS1 maint: multiple names: authors list (link)
130. Cathcart, RF. "The Ascorbate Effect in Infectious and Autoimmune Diseases". Retrieved 2008-04-04.
131. Hasslberger, S (2003-06-06). "Vitamin C could be effective against SARS". New Media Explorer. Retrieved 2008-04-04.
132. Barrett, SJ (2001-05-05). "The Dark Side of Linus Pauling's Legacy". Quackwatch. Retrieved 2008-04-04.
133. Padayatty SJ, Sun H, Wang Y; et al. (2004). "Vitamin C pharmacokinetics: implications for oral and intravenous use" (pdf). Ann. Intern. Med. 140 (7): 533–7. PMID 15068981. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
134. "American Academy of Pediatrics Commitee on Nutrition: megavitamin therapy for childhood psychoses and learning disabilities". Pediatrics. 58 (6): 910–2. 1976. PMID 995522.
135. Rosenbloom, M (2007-12-12). emedicine "Toxicity, vitamin". eMedicine. Retrieved 2008-04-04. {{cite web}}: Check |url= value (help)
136. Rapola JM, Virtamo J, Ripatti S; et al. (1997). "Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction". Lancet. 349 (9067): 1715–20. doi:10.1016/S0140-6736(97)01234-8. PMID 9193380. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
137. Arroyave G (1988). "". Arch Latinoam Nutr (in Spanish; Castilian). 38 (3): 589–98. PMID 3153129.{{cite journal}}: CS1 maint: unrecognized language (link)
138. Blair KA (1986). "Vitamin supplementation and megadoses". Nurse Pract. 11 (7): 19–26, 31–6. PMID 3737019.
139. Roberts HJ (1995). "Vitamin E". Lancet. 345 (8951): 737. PMID 7885163.
140. Bégin M, Kaegi E (1999). "Unconventional therapies and cancer" (pdf). CMAJ. 161 (6): 686–7. PMID 10513271.
141. Saul, AW (2005-05-12). "Testimony by Andrew W. Saul before the Government of Canada, House of Commons Standing Committee on Health, regarding natural health product safety". Retrieved 2008-04-04.
142. ^ Kline K, Lawson KA, Yu W, Sanders BG (2007). "Vitamin E and cancer". Vitam. Horm. 76: 435–61. doi:10.1016/S0083-6729(07)76017-X. PMID 17628185.{{cite journal}}: CS1 maint: multiple names: authors list (link)
143. Cheeseman KH, Holley AE, Kelly FJ, Wasil M, Hughes L, Burton G (1995). "Biokinetics in humans of RRR-alpha-tocopherol: the free phenol, acetate ester, and succinate ester forms of vitamin E". Free Radic. Biol. Med. 19 (5): 591–8. PMID 8529918. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
144. Rigotti A (2007). "Absorption, transport, and tissue delivery of vitamin E". Mol. Aspects Med. 28 (5–6): 423–36. doi:10.1016/j.mam.2007.01.002. PMID 17320165.
145. ^ Vitamin E Micronutrient Information Center, Linus Pauling Institute, Accessed31 May 2008
146. Traber MG (2006). "How much vitamin E? ... Just enough!". Am. J. Clin. Nutr. 84 (5): 959–60. PMID 17093143. {{cite journal}}: Unknown parameter |month= ignored (help)
147. Gaziano JM (2004). "Vitamin E and cardiovascular disease: observational studies". Ann. N. Y. Acad. Sci. 1031: 280–91. doi:10.1196/annals.1331.028. PMID 15753154. {{cite journal}}: Unknown parameter |month= ignored (help)
148. Hemilä H, Miller ER (2007). "Evidence-based medicine and vitamin E supplementation". Am. J. Clin. Nutr. 86 (1): 261–2, author reply 262–4. PMID 17616790. {{cite journal}}: Unknown parameter |month= ignored (help)
149. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ (2003). "Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials". Lancet. 361 (9374): 2017–23. doi:10.1016/S0140-6736(03)13637-9. PMID 12814711.{{cite journal}}: CS1 maint: multiple names: authors list (link)
150. Stocker R (2007). "Vitamin E". Novartis Found. Symp. 282: 77–87, discussion 87–92, 212–8. PMID 17913225.
151. Cherubini A, Vigna GB, Zuliani G, Ruggiero C, Senin U, Fellin R (2005). "Role of antioxidants in atherosclerosis: epidemiological and clinical update". Curr. Pharm. Des. 11 (16): 2017–32. PMID 15974956.{{cite journal}}: CS1 maint: multiple names: authors list (link)
152. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E (2005). "Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality". Ann. Intern. Med. 142 (1): 37–46. PMID 15537682.{{cite journal}}: CS1 maint: multiple names: authors list (link)
153. Carter, T. Responses and Comments: High-Dosage Vitamin E Supplementation and All-Cause Mortality, Ann Intern Med. 2005 Jul 19;143(2):155; responses 150-160
154. Bjelakovic G, Nikolova D, Gluud L, Simonetti R, Gluud C (2007). "Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis". JAMA. 297 (8): 842–57. PMID 17327526.{{cite journal}}: CS1 maint: multiple names: authors list (link)
155. Study Citing Antioxidant Vitamin Risks Based On Flawed Methodology, Experts Argue News release from Oregon State University published on ScienceDaily, Accessed 19 April 2007
156. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C (2008). "Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases". Cochrane Database of Systematic Reviews (2): CD007176. doi:10.1002/14651858.CD007176.{{cite journal}}: CS1 maint: multiple names: authors list (link)
157. M Walker, New/Old Findings on Unique Vitamin E, Townsend Letter for Doctors and Patients, No. 111, 1992, p. 826
158. Hoffer, A. The Finnish Antioxidant and Lung Cancer Study
159. Jiang Q, Christen S, Shigenaga MK, Ames BN (2001). "gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention". Am. J. Clin. Nutr. 74 (6): 714–22. PMID 11722951.{{cite journal}}: CS1 maint: multiple names: authors list (link)
160. MA Somerville (2004) The Ethical Canary: Science, Society and the Human Spirit, pp 175-179, McGill-Queen's University Press; 1 ed, ISBN 0773527842
161. Sask. court rules boy with cancer can't pick treatment CBC, Friday, November 10, 2000, Accessed 07 April 2008
162. Hoffer A, "The Politics of Medical Research" J Orthomol Med, vol 8, no 1, 1993
163. Klenner, FR. Observations On the Dose and Administration of Ascorbic Acid When Employed Beyond the Range Of A Vitamin. Human Pathology Journal of Applied Nutrition Vol. 23, No's 3 & 4, Winter 1971.
164. Klenner FR. Virus Pneumonia and Its Treatment With Vitamin C. Southern Med Surg, v110, no 2, p36, 1948.
165. Klenner FR. The Treatment of Poliomyelitis and Other Virus Diseases with Vitamin C, Southern Med Surg, v111, no 7, p209, 1949.
166. Klenner FR. The Use of Vitamin C as an Antibiotic. J Appl Nutr, vol 6, p274, 1953
167. Multivitamin found to slow pace of HIV, Study examined Tanzanian women, The Boston Globe, July 1, 2004
168. HD Foster Treating AIDS with Nutrition.
169. RF Cathcart, Vitamin C in the Treatment of Acquired Immune Deficiency Syndrome (AIDS), Medical Hypotheses 14:423-433, 1984
170. Priestly JC. Highly Beneficial Results in the Treatment of AIDS, J Orthomolecular Med, 1991, Vol. 6, No.3 & 4, p174
171. Irlam JH, Visser ME, Rollins N, Siegfried N (2005). "Micronutrient supplementation in children and adults with HIV infection". Cochrane Database Syst Rev (4): CD003650. PMID 16235333.{{cite journal}}: CS1 maint: multiple names: authors list (link)
172. Frei, Balz, LPI Research Newsletter - Spring 2006, Linus Pauling Institute, June ,2006. available online
173. OMACOR deal signed with new Euro partners, HYDRO, 11 Dec 2001
174. fibrinolytic activity of nattokinase, Miyazaki Medical College, Japan
175. Coenzyme Q10, prescribed for CHF in Japan since 1974, AAFP
176. Kaitin, KI, Brown, J. 1995. A Drug Lag Update. Drug Information Journal 29:361–73
177. Hoffer, Abram, History, Journal of Orthomolecular Medicine. available online

Further reading

Support

• Abram Hoffer (1998) Putting It All Together: The New Orthomolecular Nutrition, McGraw-Hill, ISBN 0-87983-633-4
• Abram Hoffer, M.D. with Linus Pauling (2004) Healing Cancer: Complementary Vitamin & Drug Treatments, CCNM Press, ISBN 1-897025-11-4
• David Moss (2000) Ph.D, Antioxidants Against Cancer, Equinox Press , ISBN 1881025284
• Pauling, Linus (1986) How to Live Longer and Feel Better, W. H. Freeman and Company, ISBN 0-380-70289-4
• Roger J. Williams, Dwight K. Kalita (1979) Physician's Handbook on Orthomolecular Medicine, Keats Publishing, ISBN 0-87983-199-5
• J. Alexander (2001) LABORATORY EVALUATIONS IN MOLECULAR MEDICINE: Nutrients, Toxicants and Cell Regulators. Inst. for Advances in Mol. Med., ISBN 0967394910
• Melvyn R. Werbach, Jeffrey Moss (1999) Textbook of Nutritional Medicine, Third Line Press, ISBN 0-9618550-9-6
• Joseph E. Pizzorno, Jr., Michael T. Murray (November 2005) Textbook of Natural Medicine, 3rd edition, Churchill Livingstone, ISBN 0-443-07300-7 · 2368pp
• Richard P. Huemer (ed.) (1986) The Roots of Molecular Medicine: A Tribute to Linus Pauling, W. H. Freeman and Company, ISBN 0-7167-1761-1 · 290pp

Criticism

• Barrie R. Cassileth (1998) Alternative medicine handbook: the complete reference guide to alternative and complementary therapies. New York: W.W.Norton & Co., ISBN 0-393-04566-8

External links

Support

• Journal of Orthomolecular Medicine
• orthomolecular.org
• Orthomolecular Medicine Online
• Official website for the International Society of Orthomolecular Medicine
• Linus Pauling Institute website
• Orthomolecular Vitamin Information Centre
• DoctorYourself.com - Personal site of Andrew Saul PhD, Contributing Editor for the Journal of Orthomolecular Medicine.
• Index orthomolecular research pages, Orthomolecular Education Foundation SOE (Netherlands)

Criticism

• Biologically Based Practices: An Overview, National Institute of Health National Center for Complementary and Alternative Medicine
• Food, Health and Well-Being in British Columbia. BC Provincial Health Officer’s Annual Report 2005.
• Should We "Thank God" for Julian Whitaker?, American Council on Science and Health, 1999
• Recommendations of the NCAHF Task Force on Supplement Abuse (1987)

• Alternative medicine
• Orthomolecular medicine
• Biologically based therapies